Mesalamine, but not sulfasalazine, reduces the risk of colorectal neoplasia in patients with inflammatory bowel disease: An agent-specific systematic review and meta-analysis

Inflammatory Bowel Diseases

Volumn 21, Issue 11, 2015, Pages 2562-2569

  O'Connor, Anthony ^a,b   Packey, Christopher D ^a   Akbari, Mona ^a   Moss, Alan C ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

Author keywords

cancer; inflammatory bowel disease; mesalamine; meta analysis; sulfasalazine

Indexed keywords

MESALAZINE; SALAZOSULFAPYRIDINE; NONSTEROID ANTIINFLAMMATORY AGENT;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PATIENT; CANCER RISK; COLORECTAL CANCER; COLORECTAL TUMOR; DOSE RESPONSE; HUMAN; INFLAMMATORY BOWEL DISEASE; META ANALYSIS; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; COLORECTAL NEOPLASMS; COMPLICATION; INFLAMMATORY BOWEL DISEASES; RISK ASSESSMENT;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLORECTAL NEOPLASMS; HUMANS; INFLAMMATORY BOWEL DISEASES; MESALAMINE; RISK ASSESSMENT; SULFASALAZINE;

EID: 84945273087     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000540     Document Type: Article

References (60)

1. Ekbom A, Helmick C, Zack M, et al. Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med. 1990;323:1228.
2. Ekbom A, Helmick C, Zack M, et al. Increased risk of large-bowel cancer in Crohn's disease with colonic involvement. Lancet. 1990;336:357.
3. Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-Analysis. Gut. 2001;48:526-535.
4. Friedman S, Rubin PH, Bodian C, et al. Screening and surveillance colonoscopy in chronic Crohn's colitis. Gastroenterology. 2001;120:820-826.
5. Jess T, Simonsen J, Jørgensen KT, et al. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology. 2012;143:375-381.
6. Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease. Gastroenterology. 2010;138:738-745.
7. Leighton JA, Shen B, Baron TH, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc. 2006;63:558-565.
8. Kornbluth A, Sachar DB. Ulcerative colitis practice guidelines in adults. American college of gastroenterology, practice parameters committee. Am J Gastroenterol. 2010;105:501-523.
9. Cairns SR, Scholefield JH, Steele RJ, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666-689.
10. Annese V, Daperno M, Rutter MD, et al. European evidence based consensus for endoscopy in inflammatory bowel disease. J Crohns Colitis. 2013;7:982-1018.
11. Pinczowski D, Ekbom A, Baron J, et al. Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control study. Gastroenterology. 1994;107:117-120.
12. Kaiser GC, Yan F, Polk DB. Mesalamine blocks tumor necrosis factor growth inhibition and nuclear factor kappa B activation in mouse colonocytes. Gastroenterology. 1999;116:602-609.
13. Velayos FS, Terdiman JP, Walsh JM. Effect of 5-Aminosalicylate use on colorectal cancer and dysplasia risk: a systematic review and metaanalysis of observational studies. Am J Gastroenterol. 2005;100: 1345-1353.
14. Zhao LN, Li JY, Yu T, et al. 5-Aminosalicylates reduce the risk of colorectal neoplasia in patients with ulcerative colitis: an updated meta-Analysis. PLoS One. 2014;9:e94208.
15. Nguyen GC, Gulamhusein A, Bernstein CN. 5-Aminosalicylic acid is not protective against colorectal cancer in inflammatory bowel disease: a meta-Analysis of non-referral populations. Am J Gastroenterol. 2012; 107:1298-1304.
16. Higgins JPT, Green S. Cochrane handbook for Systematic Reviews of Interventions [updated March 2011]. The Cochrane Collaboration; 2011.
17. Moher D, Liberati A, Tetzlaff J, et al; PRISMA Group. Preferred reporting items for systematic reviews and meta-Analyses: the PRISMA statement. Ann Intern Med. 2009;151:264-269.
18. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-Analyses. Available at: http://www.ohri.ca/programs/clinical-epidemiology/ oxford.htm. Accessed January 1, 2008.
19. DerSimonian R, Laird N. Meta-Analysis in clinical trials. Control Clin-Drials. 1986;7:177-188.
20. Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-Analyses. BMJ. 2003;327:557-560.
21. Eaden J, Abrams K, Ekbom A, et al. Colorectal cancer prevention in ulcerative colitis: a case-control study. Aliment Pharmacol Ther. 2000; 14:145-153.
22. Jess T, Loftus EV Jr, Velayos FS, et al. Risk factors for colorectal neoplasia in inflammatory bowel disease: a nested case-control study from Copenhagen county, Denmark and Olmsted county, Minnesota. Am J Gastroenterol. 2007;102:829-836.
23. Lashner BA, Provencher KS, Seidner DL, et al. The effect of folic acid supplementation on the risk for cancer or dysplasia in ulcerative colitis. Gastroenterology. 1997;112:29-32.
24. Rubin DT, Huo D, Kinnucan JA, et al. Inflammation is an independent risk factor for colonic neoplasia in patients with ulcerative colitis: a casecontrol study. Clin Gastroenterol Hepatol. 2013;11:1601-1608.e1-4.
25. Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology. 2004;126:451-459.
26. Terdiman JP, Steinbuch M, Blumentals, et al. 5-Aminosalicylic acid therapy and the risk of colorectal cancer among patients with inflammatory bowel disease. Inflamm Bowel Dis. 2007;13:367-371.
27. van Staa TP, Card T, Logan RF, et al. 5-Aminosalicylate use and colorectal cancer risk in inflammatory bowel disease: a large epidemiological study. Gut. 2005;54:1573-1578.
28. Moody GA, Jayanthi V, Probert CS, et al. Long-Derm therapy with sulphasalazine protects against colorectal cancer in ulcerative colitis: a retrospective study of colorectal cancer risk and compliance with treatment in Leicestershire. Eur J Gastroenterol Hepatol. 1996;8:1179-1183.
29. Tung BY, Emond MJ, Haggitt RC, et al. Ursodiol use is associated with lower prevalence of colonic neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Ann Intern Med. 2001;134: 89-95.
30. Lindberg BU, Broomé U, Persson B. Proximal colorectal dysplasia or cancer in ulcerative colitis. The impact of primary sclerosing cholangitis and sulfasalazine: results from a 20-year surveillance study. Dis Colon Rectum. 2001;44:77-85.
31. Pardi DS, Loftus EV Jr, Kremers WK, et al. Ursodeoxycholic acid as a chemopreventive agent in patients with ulcerative colitis and primary sclerosing cholangitis. Gastroenterology. 2003;124:889-893.
32. Bernstein CN, Blanchard JF, Metge C, et al. Does the use of 5-Aminosalicylates in inflammatory bowel disease prevent the development of colorectal cancer? Am J Gastroenterol. 2003;98:2784-2788.
33. Winther KV, Jess T, Langholz E, et al. Long-Derm risk of cancer in ulcerative colitis: a population-based cohort study from Copenhagen county. Clin Gastroenterol Hepatol. 2004;2:1088-1095.
34. Velayos FS, Loftus EV Jr, Jess T, et al. Predictive and protective factors associated with colorectal cancer in ulcerative colitis: a case-control study. Gastroenterology. 2006;130:1941-1949.
35. Siegel CA, Sands BE. Risk factors for colorectal cancer in Crohn's colitis: a case-control study. Inflamm Bowel Dis. 2006;12:491-496.
36. Rubin DT, LoSavio A, Yadron N, et al. Aminosalicylate therapy in the prevention of dysplasia and colorectal cancer in ulcerative colitis. Clin Gastroenterol Hepatol. 2006;4:1346-1350.
37. Ullman T, Croog V, Harpaz N, et al. Progression to colorectal neoplasia in ulcerative colitis: effect of mesalamine. Clin Gastroenterol Hepatol. 2008; 6:1225-1230.
38. Sokol H, Cosnes J, Chazouilleres O, et al. Disease activity and cancer risk in inflammatory bowel disease associated with primary sclerosing cholangitis. World J Gastroenterol. 2008;14:3497-3503.
39. Tang J, Sharif O, Pai C, et al. Mesalamine protects against colorectal cancer in inflammatory bowel disease. Dig Dis Sci. 2010;55:1696-1703.
40. Baars JE, Looman CW, Steyerberg EW, et al. The risk of inflammatory bowel disease-related colorectal carcinoma is limited: results from a nationwide nested case-control study. Am J Gastroenterol. 2011;106: 319-328.
41. Bernstein CN, Nugent Z, Blanchard JF. 5-Aminosalicylate is not chemoprophylactic for colorectal cancer in IBD: a population based study. Am J Gastroenterol. 2011;106:731-736.
42. Kisiel JB, Loftus EV Jr, Harmsen WS, et al. Outcome of sporadic adenomas and adenoma-like dysplasia in patients with ulcerative colitis undergoing polypectomy. Inflamm Bowel Dis. 2012;18:226-235.
43. van Schaik FD, van Oijen MG, Smeets HM, et al. Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut. 2012;61:235-240.
44. Gong W, Lv N, Wang B, et al. Risk of ulcerative colitis-Associated colorectal cancer in China: a multi-center retrospective study. Dig Dis Sci. 2012;57:503-507.
45. Beaugerie L, Svrcek M, Seksik P, et al. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology. 2013;145:166-175.e8.
46. Bessissow T, Bisschops R, Ferrante M, et al. 5-Aminosalicylate is not protective from neoplasia in ulcerative colitis. Am J Gastroenterol. 2013;108:1015.
47. Nieminen U, Jussila A, Nordling S, et al. Inflammation and disease duration have a cumulative effect on the risk of dysplasia and carcinoma in IBD: a case-control observational study based on registry data. Int J Cancer. 2014;134:189-196.
48. Lead Discovery UK. Inflammatory Bowel Diseases: World Market Report 2009-2024. Sussex, United Kingdom: Lead Discovery; 2009.
49. Ham M, Moss AC. Mesalamine in the treatment and maintenance of remission of ulcerative colitis. Expert Rev Clin Pharmacol. 2012;5: 113-123.
50. Thun MJ, Namboodiri MM, Heath Jr. C.W. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325:1593-1596.
51. Smalley W, Ray WA, Daugherty J, et al. Use of nonsteroidal antiinflammatory drugs and incidence of colorectal cancer: a populationbased study. Arch Intern Med. 1999;159:161-166.
52. Arber N, Spicak J, Rácz I, et al. Five-year analysis of the prevention of colorectal sporadic adenomatous polyps trial. Am J Gastroenterol. 2011; 106:1135-1146.
53. Din FV, Theodoratou E, Farrington SM, et al. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut. 2010;59: 1670-1679.
54. Vinogradova Y, Hippisley-Cox J, Coupland C, et al. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology. 2007;133:393-402.
55. Grau MV, Sandler RS, McKeown-Eyssen G, et al. Nonsteroidal antiinflammatory drug use after 3 years of aspirin use and colorectal adenoma risk: observational follow-up of a randomized study. J Natl Cancer Inst. 2009;101:267-276.
56. Nielsen OH. Sulfasalazine intolerance. A retrospective survey of the reasons for discontinuing treatment with sulfasalazine in patients with chronic inflammatory bowel disease. Scand J Gastroenterol. 1982;17:389-393.
57. Dissanayake AS, Truelove SC. A controlled therapeutic trial of long-Derm maintenance treatment of ulcerative colitis with sulphazalazine (Salazopyrin). Gut. 1973;14:923-926.
58. Feagan BG, Macdonald JK. Oral 5-Aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2012;10: CD000544.
59. Gupta RB, Harpaz N, Itzkowitz S, et al. Histologic inflammation is a risk factor for progression to colorectal neoplasia in ulcerative colitis: a cohort study. Gastroenterology. 2007;133:1099-1105.
60. Rutter MD, Saunders BP, Wilkinson KH, et al. Cancer surveillance in longstanding ulcerative colitis: endoscopic appearances help predict cancer risk. Gut. 2004;53:1813-1816.